Abstract：
Aim: To explore general practitioners\' (GPs) views on implementing pharmacogenomic testing in Australian general practice. Methods: Semi-structured interviews were conducted with nine GPs in Australia, recruited from primary care networks. Interviews were analyzed using thematic analysis. Themes were mapped onto the Consolidated Framework for Implementation Research domains. Results: Barriers to implementation included lack of knowledge, education, standardized pharmacogenomic reports and national clinical guidelines and financial inaccessibility. Facilitators included positive exposure to pharmacogenomics, peer influences, interdisciplinary collaboration and proven clinical utility. Current uptake was minimal; however, GPs shared positive perceptions of clinical use. Conclusion: Recommendations for successful implementation include building and disseminating clinical evidence, developing national guidelines and standardized reports, incorporation into formal education and increasing financial accessibility.
What is this article about? This article describes an original research study that examines the implementation of pharmacogenomic testing in Australian general practice. Pharmacogenomic testing applies personalized genomic information to medication prescribing, as genetic differences can affect how a person metabolizes certain medications. While there is excitement about the possibilities of using pharmacogenomics, the general uptake is slow. This study looked to understand the barriers and facilitators to implementation from the perspectives of general practitioners in Australia.What were the results? Through exploratory interviews with general practitioners, this study identified that barriers to implementation include a lack of knowledge, education, standardized reports and national clinical guidelines and financial inaccessibility. Facilitators include positive exposure to pharmacogenomic testing, peer influences, interdisciplinary collaboration and proven clinical utility. Current uptake was minimal; however, GPs shared positive perceptions of the potential of testing.What do the results of the study mean? Based on the results of this study, the following recommendations were generated for successful implementation: building and disseminating clinical evidence, developing national guidelines, incorporation into formal education, establishing accessible experts and improving financial accessibility.
What is this article about? This article describes an original research study that examines the implementation of pharmacogenomic testing in Australian general practice. Pharmacogenomic testing applies personalized genomic information to medication prescribing, as genetic differences can affect how a person metabolizes certain medications. While there is excitement about the possibilities of using pharmacogenomics, the general uptake is slow. This study looked to understand the barriers and facilitators to implementation from the perspectives of general practitioners in Australia.What were the results? Through exploratory interviews with general practitioners, this study identified that barriers to implementation include a lack of knowledge, education, standardized reports and national clinical guidelines and financial inaccessibility. Facilitators include positive exposure to pharmacogenomic testing, peer influences, interdisciplinary collaboration and proven clinical utility. Current uptake was minimal; however, GPs shared positive perceptions of the potential of testing.What do the results of the study mean? Based on the results of this study, the following recommendations were generated for successful implementation: building and disseminating clinical evidence, developing national guidelines, incorporation into formal education, establishing accessible experts and improving financial accessibility.
摘要：
目的：探讨全科医生（GP）对在澳大利亚全科医生中实施药物基因组测试的看法。方法：对澳大利亚的9名全科医生进行了半结构化访谈，从初级保健网络招募。访谈采用主题分析法进行分析。主题已映射到实施研究领域的合并框架。结果：实施的障碍包括缺乏知识，教育,标准化的药物基因组学报告和国家临床指南，以及金融不可用。促进者包括积极接触药物基因组学，同伴的影响，跨学科合作和经过验证的临床实用性。电流吸收很小；然而，全科医生对临床使用有着积极的看法。结论：成功实施的建议包括建立和传播临床证据，制定国家指导方针和标准化报告，纳入正规教育，增加金融可及性。
本文是关于什么的？本文描述了一项原始的研究，该研究检查了澳大利亚一般实践中药物基因组测试的实施。药物基因组学测试将个性化基因组信息应用于药物处方，因为遗传差异会影响一个人代谢某些药物的方式。虽然人们对使用药物基因组学的可能性感到兴奋，一般的摄取是缓慢的。这项研究旨在从澳大利亚全科医生的角度了解实施的障碍和促进者。结果如何？通过对全科医生的探索性访谈，这项研究发现，实施的障碍包括缺乏知识，教育,标准化报告和国家临床指南以及财务不可用。促进者包括积极暴露于药物基因组学测试，同伴的影响，跨学科合作和经过验证的临床实用性。电流吸收很小；然而，全科医生对测试的潜力有着积极的看法。这项研究的结果是什么意思？根据这项研究的结果，为成功实施提出了以下建议：建立和传播临床证据，制定国家指导方针，纳入正规教育，建立无障碍专家，提高金融可及性。
本文是关于什么的？本文描述了一项原始的研究，该研究检查了澳大利亚一般实践中药物基因组测试的实施。药物基因组学测试将个性化基因组信息应用于药物处方，因为遗传差异会影响一个人代谢某些药物的方式。虽然人们对使用药物基因组学的可能性感到兴奋，一般的摄取是缓慢的。这项研究旨在从澳大利亚全科医生的角度了解实施的障碍和促进者。结果如何？通过对全科医生的探索性访谈，这项研究发现，实施的障碍包括缺乏知识，教育,标准化报告和国家临床指南以及财务不可用。促进者包括积极暴露于药物基因组学测试，同伴的影响，跨学科合作和经过验证的临床实用性。电流吸收很小；然而，全科医生对测试的潜力有着积极的看法。这项研究的结果是什么意思？根据这项研究的结果，为成功实施提出了以下建议：建立和传播临床证据，制定国家指导方针，纳入正规教育，建立无障碍专家，提高金融可及性。
